Now, Cook Group finished the sale of Cook Pharmica into Catalent, Inc. (NYSE: CTLT). Cook Pharmica, now called Catalent Bloomington, expands Catalent’s abilities by incorporating more drug substance and drug product expertise and capability to serve patients worldwide. The conclusion of the purchase of Cook Pharmica will strengthen Catalent’s position as a pioneer in the fast growing biologics development, analytical, production and finished product supply market.
“Now is an important one for the workers of Cook Pharmica who are now part of Catalent’s rising biologics company,” explained Pete Yonkman, president of Cook Group and Cook Medical. “It is also an important evening for Bloomington as we welcome a third key life sciences business to the area. We are excited for Catalent to be part of the expanding life sciences heart in Bloomington.”
Together with Cook Pharmica’s accessible space and expertise, Catalent creates a different biologics development and production centre of excellence within its site network. The purchase enables the Bloomington site to deepen connections with customers and grow their already successful enterprise. Catalent intends to spend aggressively in this site and in the remainder of the Catalent Biologics network to build a true global leader at the biologics marketplace, which can help Catalent to improve the lives of individuals around the world. Catalent Bloomington will stay under the direction of Tedd Green.
Along with the sale of Cook Pharmica, Cook Group recently declared the intent to buy the former GE site near Cook’s world headquarters on Bloomington’s west side. The sale is progressing as expected and Cook recently received approval by the Bloomington City Council for an in lieu of annexation arrangement on Cook properties including the projected purchase of the empty GE facility.
“We are essentially doubling down in Bloomington,” Yonkman continued. “We want more space to accommodate our expansion and also to enable us to expedite modernization and conversion of our production procedure. The flexibility that the GE space provides will permit us to purpose assemble for efficacy in our production lines.”
Cook Group is a family-owned firm with headquarters in Bloomington, Indiana. Our diverse company portfolio comprises firms operating in life sciences, business services, hotels, real estate management, and medical devices.
Launched in 1963, Cook Group companies now employ over 12,000 individuals around the world. We’re dedicated to enhancing lives by giving back to our communities, supporting our employees and their families, and also serving our customers and their patients. Learn more at www.CookGroup.com.
Cook Pharmica is a contract development and production company (CDMO) that provides biopharmaceutical companies with a distinctive One Source, One Location design for growth, clinical or business cell culture production, parenteral product manufacturing, and secondary packaging. Cook Pharmica was set in 2004, also, over the last 13 decades, Cook Pharmica has spent heavily in its own center, individuals, and processes.
Catalent is the leading global provider of advanced delivery technologies and development alternatives for drugs, biologics and consumer health products. With over 80 years serving the market, Catalent has proven expertise in bringing additional customer products to market faster, enhancing product functionality and ensuring reliable clinical and business product supply. Catalent employs over 10,000 people, including over 1,400 scientists, at over 30 centers across five continents, also in financial 2017 generated over $2 billion in yearly earnings. Catalent is headquartered in Somerset, New Jersey. For more information, visit www.Catalent.com.
View source version onto businesswire.com: http://www.businesswire.com/news/home/20171023006572/en/